TRV GP, LLC - Q4 2017 holdings

$221 Million is the total value of TRV GP, LLC's 5 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .

 Value Shares↓ Weighting
RYTM NewRHYTHM PHARMACEUTICALS, INC.$115,701,0003,981,437
+100.0%
52.29%
CTMX NewCYTOMX THERAPEUTICS, INC.$70,093,0003,320,348
+100.0%
31.68%
KALA NewKALA PHARMACEUTICALS INC.$30,590,0001,654,425
+100.0%
13.82%
EBIO NewELEVEN BIOTHERAPEUTICS, INC.$3,922,0004,841,591
+100.0%
1.77%
ZFGN NewZAFGEN, INC.$972,000210,371
+100.0%
0.44%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Mark Levin #1
  • Kevin P. Starr #2
  • Robert I. Tepper #3
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-02-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SESEN BIO, INC.13Q4 2020100.0%
RHYTHM PHARMACEUTICALS, INC.8Q3 201980.0%
CONSTELLATION PHARMACEUTICALS INC.8Q2 202096.6%
ZAFGEN, INC.7Q2 20192.0%
KALA PHARMACEUTICALS INC.3Q2 201818.6%
SESEN BIO, INC.2Q2 2021100.0%
CYTOMX THERAPEUTICS, INC.2Q1 201831.7%
01Q3 20210.0%

View TRV GP, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2021-11-05
13F-HR2021-08-11
13F-HR2021-05-12
13F-HR2021-02-16
13F-HR2020-11-06
13F-HR2020-08-07
13F-HR2020-05-11
13F-HR2020-02-05
13F-HR2019-11-04
13F-HR2019-08-06

View TRV GP, LLC's complete filings history.

Compare quarters

Export TRV GP, LLC's holdings